BAY 869766 is primarily utilized in the field of oncology research, where it serves as a potent and selective inhibitor of specific kinases involved in cancer cell proliferation and survival. Its application is particularly significant in preclinical studies aimed at understanding the molecular mechanisms of tumor growth and metastasis. Researchers employ BAY 869766 to investigate its potential in inhibiting pathways that drive cancer progression, providing insights into its efficacy as a targeted therapeutic agent. Additionally, it is used in combination studies with other anticancer drugs to evaluate synergistic effects and improve treatment outcomes. The compound’s ability to selectively target kinases makes it a valuable tool in the development of novel cancer therapies, especially for malignancies resistant to conventional treatments.